| Conclusion—Recommendation: Thromboprophylaxis is associated with survival benefit (low dose compared to no thromboprophylaxis) and is recommended for all hospitalized patients with COVID-19 with an acceptable bleeding risk profile. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.